Drug-induced Parkinsonism (DIP) is the second most common cause of parkinsonism (PK)\(^1\). Flunarizine and cinnarizine-induced parkinsonism (FCIP) is one of the most frequent forms and is commonly found in elderly female patients manifesting symmetrical motor symptoms with resting and/or postural tremor, often associated with depression, and occasionally acathisia and dyskinesia\(^1\).

FCIP was first described in Brazil in 1984 by De Melo-Souza during the IX Brazilian Congress of Neurology\(^2\). In his study, De Melo-Souza reported 5 female elderly patients with a past history of flunarizine use presenting with both PK and depression. A few years later, in 1989, De Melo-Souza and Ragazzo presented a larger series at the Annual Meeting of the American Academy of Neurology. In that series, all of the 28 patients (25 female, with a mean age of 66 years) had used flunarizine 10 mg daily for a mean time of 6 months. Along with a rigid-akineti-ic syndrome, 60% of the patients had tremor and 85% had depression. Only one patient presented with bucolingual dyskinesia and six had akathisia\(^1\).

According to Negrotti and Calzetti\(^3\) and Martí-Masso and Poza\(^4\) the clinical characteristics of cases with FCIP include: 1) Previous flunarizine or cinnarizine treatment; 2) PK diagnosed after onset of therapy with the drugs; 3) Clinical features are indistinguishable from Parkinson’s disease, with a rigidity-akineti-ic syndrome, resting and postural tremor, but usually with bilateral onset, progressing with symmetrical findings and associated depressive disorder; 4) Predominantly affects elderly female patients; 5) Remission of PK symptoms after drug discontinuation; 6) Other causes of PK (including other drugs) excluded. Curiously, the first cases presented by De Melo-Souza 25 years ago with the main clinical features of FCIP were reported by him as “the crying older little women”\(^1,2,5\).

Twenty-five years later, FCIP is widely recognized as one of the most common cause of PK and it is now being called as De Melo e Souza’s syndrome\(^1,5\).

REFERENCES

Hélio A. G. Teive*
Renato Puppi Munhoz*
Henrique B. Ferraz**

*Movement Disorders Unit/Neurology Service, Internal Medicine Department, Hospital de Clínicas da Universidade Federal do Paraná, Paraná PR, Brazil. E-mail: hgteive@mps.com.br; **Movement Disorders Unit/Neurology and Neurosurgery Department, Universidade Federal de São Paulo, São Paulo SP, Brazil.